- Emyria (EMD) reports positive bioanalytical results of its ultra-pure CBD formulation
- In a pre-clinical animal study, Emyria compared its ultra-pure cannabidiol formulation, the EMD-003 capsule, to the only registered CBD product in Australia and the US, Epidyolex oil
- Results demonstrated that EMD-003 had a greater peak concentration and improved bioavailability compared to an equivalent dose of Epidyolex over a 24-hour period
- Emyria is aiming to target registration of EMD-003 as a low-dose, over-the-counter CBD medicine with the TGA in 2022
- Company shares are up 2.74 per cent, trading at 37.5 cents
Emyria (EMD) has reported positive bioanalytical results of its ultra-pure CBD formulation.
Emyria has been working with Altasciences to develop a proprietary CBD capsule, which is made of FDA-approved ingredients.
In a pre-clinical, head-to-head animal study, Emyria compared its ultra-pure cannabidiol formulation, the EMD-003 capsule, to the only registered CBD product in Australia and the US, Epidyolex oil.
Eight canine subjects were administered single doses of EMD-003, Epidyolex and two other test formulations. For each treatment, 12 blood samples were collected over 24 hours for each subject and analysed for CBD concentration.
Results demonstrated that EMD-003 had a greater peak concentration and improved bioavailability, compared to an equivalent dose of Epidyolex over a 24-hour period. Bioavailability is a measure of the amount of can be given in a lower dose to a patient to achieve the same outcome.
Emyria’s Managing Director, Dr. Michael Winlo said he was delighted to receive the positive bioanalysis results.
“We were eager to evaluate the bioavailability of our formulation compared to the only successfully registered and reimbursed CBD oil in the market to date, Epidyolex,” Dr Winlo explained.
“These animal study results suggest Emyria has developed a novel, high performing and cost-effective CBD capsule that can meet the strict registration requirements for product quality and purity with both the TGA in Australia and the FDA in the US.”
“These results also give us the confidence to launch additional cannabinoid registration programs with the TGA and FDA based on the underlying formulation approach.”
Emyria is aiming to target registration of EMD-003 as a low-dose, over-the-counter CBD medicine with the TGA in 2022.
Company shares were up 2.74 per cent, trading at 37.5 cents at 3:17 pm AEDT.